Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome.
Sahar M El-Haggar, Sahar K Hegazy, Sherief M Abd-Elsalam...
https://pubmed.ncbi.nlm.nih.gov/34726293/Actively Recruiting
Led by Tanta University · Updated on 2020-01-03
60
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to evaluate the safety and effectiveness of two drugs, ethosuximide and pentoxifylline, for treating abdominal pain related to irritable bowel syndrome IBS. It compares these treatments to a current medication, mebeverine, to see if they provide additional relief. The study is a phase 3 clinical trial conducted with adult men and women diagnosed with IBS according to Rome criteria IV who experience moderate to severe pain. Participants are randomly assigned to one of three groups receiving either mebeverine three times daily, ethosuximide three times daily, or pentoxifylline twice daily, each for a period of three months. The trial uses a triple-blind design to monitor and compare the effects of these drugs on IBS-related abdominal pain. During the study, patients will be regularly assessed for changes in pain using the Visual Analog Scale VAS, with researchers tracking improvements over six months. Safety and any side effects are also monitored. The overall goal is to understand if ethosuximide or pentoxifylline can add benefit to existing IBS treatments under stable conditions.
CONDITIONS
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
S
Sherief Abd-Elsalam, ass. prof.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tanta University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive assigned medications to treat abdominal pain related to irritable bowel syndrome.
Regular visits to monitor treatment progress (visit frequency not specified)
Duration - 3 months
Participants are monitored for up to 3 additional months after treatment to assess safety and effectiveness.
Visits for assessment of pain and safety (visit frequency not specified)
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Sahar M El-Haggar, Sahar K Hegazy, Sherief M Abd-Elsalam...
https://pubmed.ncbi.nlm.nih.gov/34726293/Sahar M El-Haggar, Sahar K Hegazy, Sherief M Abd-Elsalam...
https://pubmed.ncbi.nlm.nih.gov/35221706/Tanta University
Lead Sponsor